Anti-Emetic Allergy: Ondansetron Anaphylaxis, QT Prolongation & Safety
Anti-emetic allergy is uncommon — true IgE-mediated anaphylaxis to ondansetron (Zofran) exists but is rare, and most adverse events attributed to anti-emetics are pharmacologic rather than allergic. Ondansetron QT prolongation prompted the FDA to withdraw the 32 mg IV dose in 2012, capping the maximum at 16 mg. Metoclopramide carries a black box warning for tardive dyskinesia. Patients suspecting anti-emetic allergy should consult an allergist to distinguish true hypersensitivity from pharmacologic effects.
Free · 5 min · Insurance accepted
Key facts
True IgE-mediated anaphylaxis to ondansetron (Zofran) exists but is rare — most adverse events attributed to anti-emetics are pharmacologic effects including QT prolongation, tardive dyskinesia, or tissue necrosis.
The FDA withdrew the 32 mg IV ondansetron dose in 2012 due to QT prolongation risk, capping the maximum single IV dose at 16 mg — a pharmacologic, not allergic, safety concern.
Metoclopramide carries a black box warning for tardive dyskinesia — a movement disorder from prolonged D2 receptor blockade — which is the most clinically significant adverse effect of this drug class.
Anti-emetics span 6 mechanistic classes (5-HT3, NK1, D2, H1, corticosteroid, cannabinoid) — a reaction to ondansetron carries no cross-reactivity implications for metoclopramide or aprepitant.
What Is Anti-Emetic Allergy?
Anti-emetic allergy refers to hypersensitivity reactions triggered by medications used to prevent nausea and vomiting, though true immune-mediated allergy to these drugs is rare relative to the pharmacologic adverse effects that dominate clinical practice.
Anti-emetics span six mechanistic classes: 5-HT3 antagonists (ondansetron, granisetron, palonosetron), NK1 antagonists (aprepitant, fosaprepitant), D2 antagonists (metoclopramide, prochlorperazine, promethazine, droperidol), H1 antihistamines used as anti-emetics (meclizine, dimenhydrinate), corticosteroid adjuncts (dexamethasone), and cannabinoids (dronabinol, nabilone).
The clinical reality is that ondansetron QT prolongation, metoclopramide tardive dyskinesia, and promethazine tissue necrosis are far more common and clinically significant than true allergic reactions. Each carries an FDA black box warning or major labeling change that shapes prescribing practice. Patients who search for anti-emetic allergy are often experiencing one of these pharmacologic adverse events rather than an immune-mediated hypersensitivity, making accurate clinical distinction essential.
Anti-emetics represent one of the most pharmacologically diverse drug classes in clinical medicine, spanning six distinct mechanistic subgroups that target different receptors in the vomiting reflex arc. This diversity means that the allergy and adverse effect profile varies dramatically between subclasses — a reaction to ondansetron (a 5-HT3 antagonist) carries no cross-reactivity implications for metoclopramide (a D2 antagonist) or aprepitant (an NK1 antagonist). Understanding which subclass caused the reaction is therefore essential for identifying safe alternatives.
Anti-Emetic Reaction Symptoms
Recognizing symptoms early helps you get the right treatment faster.
Urticaria (hives)
moderateItchy, raised welts appearing after ondansetron or other 5-HT3 antagonist administration, suggesting possible IgE-mediated hypersensitivity.
Angioedema
severeSwelling of the face, lips, tongue, or throat after anti-emetic exposure. Potentially life-threatening if airway is compromised.
Anaphylaxis
severeRare but documented systemic allergic reaction to ondansetron with hypotension, airway compromise, and cardiovascular collapse requiring immediate epinephrine.
QT prolongation symptoms (palpitations, syncope)
severeCardiac rhythm disturbance from ondansetron hERG channel blockade. NOT allergy. Risk is highest with IV dosing and concurrent QT-prolonging drugs.
Acute dystonic reaction
moderateInvoluntary muscle contractions of the face, neck, or back from metoclopramide D2 blockade. Pharmacologic, not allergic. More common in young women and children.
Tardive dyskinesia
severeInvoluntary repetitive movements of the face, tongue, and limbs from chronic metoclopramide use. Potentially irreversible even after drug discontinuation.
Injection site tissue necrosis
severeSevere tissue damage from promethazine IV extravasation, causing gangrene and compartment syndrome that may require surgical debridement or amputation.
Photoallergic contact dermatitis
mildSkin rash on sun-exposed areas caused by topical or systemic promethazine through a genuine Type IV immune-mediated photoallergy mechanism.
When to see a doctor
True anti-emetic allergy symptoms are uncommon and must be distinguished from the more prevalent pharmacologic adverse effects of these medications. Ondansetron hypersensitivity presents with urticaria, angioedema, and in rare cases anaphylaxis — if you experience hives, facial swelling, or difficulty breathing after receiving ondansetron, seek emergency medical care immediately. Stevens-Johnson syndrome has been reported with ondansetron in isolated case reports. Pharmacologic adverse effects are far more common than allergy. Ondansetron QT prolongation can cause palpitations, syncope, or cardiac arrest — these are cardiac toxicity symptoms, not allergic responses. Metoclopramide can cause acute dystonic reactions (involuntary muscle contractions, particularly in young women and children), tardive dyskinesia (irreversible involuntary movements), and rarely neuroleptic malignant syndrome. Promethazine causes tissue necrosis at injection sites and paradoxical agitation in elderly patients.
Can Anti-Emetic Reactions Affect Breathing?
Anti-emetics do not cause chronic asthma, but ondansetron anaphylaxis can include bronchospasm as part of the systemic allergic reaction. This is rare and treated with standard anaphylaxis protocols including intramuscular epinephrine. Promethazine, as a first-generation antihistamine with sedative properties, carries a contraindication in children under 2 years due to risk of fatal respiratory depression — this is a pharmacologic effect on the brainstem respiratory center, not bronchospasm. Diphenhydramine and hydroxyzine, when used as anti-emetics, have H1 antihistamine properties that may actually provide mild bronchodilation in patients with concurrent allergic asthma. If you have asthma and require anti-emetic therapy, no dose adjustments are needed for most anti-emetics, but inform your prescriber about your respiratory history.
Complications of Anti-Emetic Adverse Events
The most significant complication is ondansetron-induced torsades de pointes, a life-threatening ventricular arrhythmia that prompted the FDA to withdraw the 32 mg single IV dose in June 2012 and cap the maximum at 16 mg. Patients with congenital long QT syndrome, electrolyte abnormalities, or concurrent QT-prolonging medications face the highest risk. Metoclopramide tardive dyskinesia is irreversible in some patients even after drug discontinuation, which is why the 2009 FDA black box warning limits metoclopramide to short-term use (preferably under 12 weeks). Promethazine tissue necrosis has resulted in limb amputations when IV extravasation was not immediately recognized. These complications underscore the importance of distinguishing pharmacologic adverse effects from true allergy — the clinical management and prevention strategies differ entirely. Metoclopramide-induced tardive dyskinesia, characterized by repetitive involuntary movements of the face, tongue, and extremities, may be irreversible even after drug discontinuation, particularly in elderly patients and those treated for longer than 12 weeks. The incidence of tardive dyskinesia reaches approximately 20% in long-term users, making this one of the most serious non-allergic complications in the anti-emetic class. Droperidol carries its own distinct risk profile — the FDA 2001 boxed warning for QT prolongation and cardiac death effectively removed it from routine anti-emetic practice, though it is still occasionally used at low doses in anesthesia settings under continuous cardiac monitoring.
Torsades de pointes from ondansetron
Life-threatening ventricular arrhythmia caused by hERG channel blockade and QT prolongation, particularly with high IV doses or in patients with baseline QT abnormalities.
Irreversible tardive dyskinesia
Chronic involuntary facial and limb movements from prolonged metoclopramide D2 blockade that may persist indefinitely after drug discontinuation.
Tissue gangrene from promethazine extravasation
Severe perivascular chemical injury from IV promethazine causing compartment syndrome, tissue necrosis, and in severe cases requiring amputation.
Serotonin syndrome
Rare but potentially fatal interaction when ondansetron is combined with SSRIs, SNRIs, or MAOIs, causing altered mental status, neuromuscular hyperactivity, and autonomic instability.
What Causes Anti-Emetic Reactions?
Ondansetron hypersensitivity — urticaria, angioedema, and rare anaphylaxis — is documented by Ye and colleagues (Allergy Asthma Immunol Res, 2014) and involves IgE-mediated mechanisms directed against the carbazole backbone shared by most 5-HT3 antagonists. Cross-reactivity within the 5-HT3 class is expected because of this structural similarity, though granisetron has a different indazole structure and is often tolerated after ondansetron reactions.
How it works
Ondansetron anaphylaxis follows the classical Type I IgE-mediated pathway with mast cell degranulation targeting the shared carbazole backbone of 5-HT3 antagonists. Ondansetron QT prolongation is a pharmacologic effect involving cardiac ion channel (hERG) blockade that delays ventricular repolarization. Metoclopramide tardive dyskinesia results from chronic D2 receptor antagonism causing dopamine receptor supersensitivity in the striatum. Promethazine tissue necrosis involves direct chemical injury to perivascular tissues from extravasation, not an immune mechanism.
Metoclopramide (Reglan) causes tardive dyskinesia through chronic D2 receptor blockade in the basal ganglia — this is a neurologic pharmacologic effect, not an allergy, but it received an FDA black box warning in February 2009 because approximately 20 percent of long-term users develop this potentially irreversible movement disorder. Promethazine (Phenergan) causes severe tissue injury from IV extravasation — gangrene, compartment syndrome, and sometimes amputation — prompting an FDA boxed warning in 2009 recommending deep intramuscular injection rather than IV administration. Promethazine also causes photoallergic contact dermatitis through a genuine Type IV immune mechanism. Droperidol received an FDA black box warning in 2001 for QT prolongation and cardiac death, largely removing it from routine anti-emetic practice.
The carbazole backbone shared by most 5-HT3 antagonists is the structural feature driving within-class cross-reactivity. Granisetron, which has an indazole rather than carbazole backbone, is structurally distinct enough that it is often tolerated by patients who reacted to ondansetron. Palonosetron, a second-generation 5-HT3 antagonist with a 40-hour half-life and different binding kinetics, also represents a potential alternative, though clinical cross-reactivity data remain limited. The D2 antagonist subclass carries risks that are predominantly neurologic rather than immunologic — extrapyramidal symptoms, tardive dyskinesia, and neuroleptic malignant syndrome are all consequences of dopamine receptor blockade.
Risk factors to watch for
Prior reaction to a 5-HT3 antagonist
Cross-reactivity within the setron class due to the shared carbazole backbone means a reaction to ondansetron may predict reactions to dolasetron and palonosetron.
Congenital long QT syndrome
Patients with prolonged QT interval or electrolyte abnormalities (hypokalemia, hypomagnesemia) face higher risk of ondansetron-induced arrhythmia.
Chronic metoclopramide use beyond 12 weeks
Tardive dyskinesia incidence rises dramatically with prolonged metoclopramide use, affecting approximately 20 percent of long-term users.
IV promethazine administration
Intravenous rather than intramuscular promethazine substantially increases the risk of tissue necrosis from extravasation or perivascular injection.
The Allergy Cascade
Exposure
Allergen contact
Detection
Immune recognition
IgE Response
Antibody production
Mast Cells
Histamine release
Symptoms
Allergic reaction
1.Exposure
Allergen contact
2.Detection
Immune recognition
3.IgE Response
Antibody production
4.Mast Cells
Histamine release
5.Symptoms
Allergic reaction
Diagnosing Anti-Emetic Allergy
Distinguishing true anti-emetic allergy from pharmacologic adverse effects requires careful clinical history and, when indicated, structured allergist-led drug provocation testing. The key diagnostic question is whether the reaction involved immune-mediated features (urticaria, angioedema, anaphylaxis) or pharmacologic features (QT prolongation, dystonia, sedation, tissue necrosis from extravasation). For suspected ondansetron IgE-mediated allergy, an allergist can perform graded drug challenge with ondansetron or, if cross-reactivity is suspected, with the structurally distinct granisetron (indazole backbone rather than carbazole). Serum tryptase elevation during an acute reaction supports an allergic mechanism. For promethazine photoallergic contact dermatitis, patch testing with UV exposure confirms the Type IV diagnosis. For evaluation of concurrent IgE-mediated environmental allergies that may be contributing to nausea triggers or overall allergic burden, services like Curex offer at-home allergy testing panels covering 40+ allergens with results typically within 5 days and insurance accepted. The anti-emetic reaction itself requires in-clinic allergist evaluation. Differentiating true ondansetron hypersensitivity from the far more common QT prolongation adverse effect requires careful electrocardiographic assessment. Patients who experienced syncope, palpitations, or cardiac-sounding symptoms after ondansetron should have a baseline ECG reviewed for congenital or acquired long QT before labeling the reaction as allergy. Drug provocation testing with an alternative 5-HT3 antagonist such as granisetron, performed under allergist supervision with continuous cardiac monitoring, can confirm or exclude cross-class tolerance.
Drug Provocation Test with Alternative 5-HT3 Antagonist
Graded oral or IV challenge with granisetron (structurally distinct indazole backbone) in patients with confirmed ondansetron hypersensitivity, to identify a tolerated alternative within the same drug class.
Serum Tryptase During Acute Reaction
Blood test drawn within 1 to 2 hours of an acute reaction to determine whether mast cell degranulation occurred, supporting an IgE-mediated allergic mechanism versus a pharmacologic adverse effect.
Electrocardiogram (ECG)
Baseline and post-dose ECG monitoring to identify QT prolongation from ondansetron or droperidol, distinguishing cardiac toxicity from allergic reaction.
Photopatch Testing for Promethazine
Epicutaneous application of promethazine with subsequent UV exposure to confirm Type IV photoallergic contact dermatitis, distinguishing it from phototoxic or pharmacologic skin reactions.
Test from home with Curex
Skip the clinic visit. Curex sends an at-home allergy test kit to your door, and a board-certified allergist reviews your results to build a personalized treatment plan.
Take the allergy quizCompare Treatment Options
See how different approaches stack up for managing your allergy symptoms long-term.
Traditional
Allergy Shots (SCIT)
Immunotherapy (SLIT)
RecommendedTreats root cause
Long-lasting relief
At-home treatment
No office visits
Low side effects
Estimated cost
Traditional
- Treats root cause
- Long-lasting relief
- At-home treatment
- No office visits
- Low side effects
- Estimated cost
Allergy Shots (SCIT)
- Treats root cause
- Long-lasting relief
- At-home treatment
- No office visits
- Low side effects
- Estimated cost
Immunotherapy (SLIT)
Recommended- Treats root cause
- Long-lasting relief
- At-home treatment
- No office visits
- Low side effects
- Estimated cost
The long-term solution to allergies
Instead of masking symptoms, immunotherapy retrains your immune system.
Patients who find themselves frequently needing anti-emetics for allergic reactions — nausea from severe allergic rhinitis, motion sickness compounded by sinus congestion, or GI symptoms during food allergy episodes — may benefit from addressing the underlying allergy triggers rather than relying solely on anti-nausea medications. Anti-emetic allergy itself cannot be treated with immunotherapy because these are drug hypersensitivity reactions, not IgE-mediated environmental allergy. The management of confirmed ondansetron or other anti-emetic allergy is avoidance plus alternative anti-emetic selection. However, if you also have IgE-mediated respiratory or environmental allergies that contribute to nausea-triggering symptoms, sublingual immunotherapy (SLIT drops) can address those underlying triggers. Providers like Curex offer at-home SLIT drops starting at $39/month for dust mite, pollen, and pet dander allergies, reducing the allergic inflammation that may be contributing to your overall symptom burden. For the anti-emetic reaction itself, an allergist-led drug provocation test with an alternative agent determines safe treatment options.
Identify the Reaction Type
Work with your allergist to determine whether your anti-emetic reaction is IgE-mediated allergy (urticaria, anaphylaxis) or pharmacologic toxicity (QT prolongation, dystonia, tissue necrosis).
Test Alternative Anti-Emetics
If ondansetron allergy is confirmed, graded drug provocation with granisetron or an NK1 antagonist identifies safe alternatives for future anti-emetic needs.
Evaluate Environmental Allergy Triggers
If nausea is part of a broader allergic syndrome, identify environmental triggers contributing to your symptoms through comprehensive allergy testing.
Address Underlying Allergies with Immunotherapy
Sublingual immunotherapy for environmental allergens can reduce the overall allergic burden that may be contributing to nausea and GI symptoms during allergy episodes.
“Granisetron tolerance after ondansetron allergy is achieved in the majority of patients; environmental allergy immunotherapy shows 60-85% symptom reduction in clinical trials”
Treat your Anti-Emetic allergy at the source
See if at-home sublingual allergy drops fit your allergies — a 2-minute quiz, designed by board-certified allergists, with no needles and no clinic visits.
- 4.8/5Patient rating
- From $39/moWith insurance
- 50K+Patients treated
- HSA/FSAEligible
Living With Anti-Emetic Sensitivity
If you have confirmed allergy to one anti-emetic, you have multiple alternative classes available because anti-emetics work through at least six different receptor mechanisms. This pharmacologic diversity means that cross-class reactions are essentially absent — ondansetron allergy does not predict reactions to aprepitant, meclizine, dexamethasone, or scopolamine. The practical challenge is ensuring that your allergy is accurately documented and communicated to all healthcare providers. Chemotherapy patients, surgical candidates, and individuals with chronic nausea conditions should have a clear anti-emetic plan that specifies both the drug to avoid and the tolerated alternatives.
Pre-Surgical Anti-Emetic Planning
Before any surgical procedure, inform the anesthesia team about your specific anti-emetic allergy so that alternative PONV prophylaxis is planned. Granisetron, aprepitant, and dexamethasone are common safe alternatives.
Chemotherapy Anti-Emetic Regimen Adjustment
Work with your oncologist to design a chemotherapy anti-emetic protocol that avoids the offending drug. Multi-class combination regimens provide effective nausea control even without ondansetron.
Emergency Department Communication
If you present to the emergency department with nausea, clearly communicate your specific anti-emetic allergy and known tolerated alternatives to prevent inadvertent administration of the offending drug.
Seasonal Patterns
January - December
medium intensity
Prevention Tips
Request ECG Before High-Dose IV Ondansetron
If you have cardiac risk factors or take other QT-prolonging medications, ask your physician about baseline ECG monitoring before receiving IV ondansetron.
Limit Metoclopramide Duration
Do not use metoclopramide for longer than 12 weeks without explicit physician reassessment. The tardive dyskinesia risk increases substantially with prolonged use.
Avoid IV Promethazine When Possible
Request intramuscular injection or an alternative anti-emetic instead of IV promethazine to prevent the risk of tissue necrosis from extravasation.
Document Anti-Emetic Allergies Clearly
Ensure your medical record specifies the exact anti-emetic that caused the reaction, the type of reaction, and tolerated alternatives to guide future prescribing.
Outlook for Anti-Emetic Allergy
The prognosis for patients with anti-emetic allergy is excellent because the breadth of available anti-emetic classes ensures that effective alternatives exist for every clinical scenario. Ondansetron-allergic patients can typically use granisetron, NK1 antagonists, antihistamine anti-emetics, scopolamine, or dexamethasone without cross-reactivity. For patients whose anti-emetic adverse events were pharmacologic rather than allergic — QT prolongation, tardive dyskinesia, or tissue necrosis — the events are typically managed by drug discontinuation and class switching rather than allergy-specific treatment. Accurate labeling of the reaction type in the medical record is the most important long-term management step.
Key takeaways
Multiple anti-emetic classes with different receptor mechanisms ensure alternatives exist for every clinical scenario
Granisetron tolerance is common after ondansetron allergy due to their different structural backbones
Accurate documentation of whether the reaction was allergic versus pharmacologic guides appropriate future prescribing
Diet and Anti-Emetic Use
Dietary factors do not cause anti-emetic allergy, but diet plays a role in managing the nausea that drives anti-emetic use. Small, frequent meals of bland foods and ginger-containing products have evidence supporting their anti-nausea effects and may reduce medication dependence in mild cases. Patients taking ondansetron should be aware that severe electrolyte depletion from persistent vomiting — particularly hypokalemia and hypomagnesemia — can worsen QT prolongation risk. Maintaining electrolyte-replenishing fluids during illness helps mitigate this pharmacologic concern.
Foods that help
Ginger (tea, supplements, candied)
Clinical trials support ginger's anti-nausea properties for pregnancy-related, chemotherapy-related, and post-operative nausea, potentially reducing anti-emetic medication need.
Electrolyte-replenishing fluids
Maintaining potassium and magnesium levels during vomiting illness reduces the QT prolongation risk associated with ondansetron use.
Most patients who say they are allergic to Zofran are actually describing pharmacologic side effects — nausea paradox, headache, or constipation — not IgE-mediated reactions. Genuine ondansetron anaphylaxis exists but is rare enough that a positive allergy claim should prompt allergist evaluation before permanently avoiding a valuable antiemetic drug class.
Frequently Asked Questions
True IgE-mediated allergy to ondansetron is rare but documented, with Ye and colleagues reporting cases of urticaria, angioedema, and anaphylaxis in Allergy Asthma Immunol Res (2014). Stevens-Johnson syndrome case reports also exist. Most adverse events attributed to ondansetron, however, are pharmacologic — QT prolongation causing palpitations or syncope, headache, and constipation. An allergist can distinguish true allergy from pharmacologic toxicity through clinical history, serum tryptase measurement during an acute reaction, and if needed, graded drug provocation testing with a structurally different alternative like granisetron.
The FDA withdrew the 32 mg single IV ondansetron dose in June 2012 after determining that this dose caused clinically significant QT interval prolongation, increasing the risk of torsades de pointes — a life-threatening ventricular arrhythmia. The FDA safety communications in 2011 and 2012 revised the label to cap the maximum single IV dose at 16 mg for chemotherapy-induced nausea prevention and recommended lower doses for post-operative nausea. This was a pharmacologic cardiac toxicity concern related to hERG potassium channel blockade, not an allergic reaction. Patients with congenital long QT syndrome should avoid ondansetron entirely.
Tardive dyskinesia from metoclopramide (Reglan) is an involuntary movement disorder — rhythmic, repetitive movements of the face, tongue, jaw, and sometimes the limbs — caused by chronic D2 dopamine receptor blockade in the basal ganglia. The FDA added a black box warning in February 2009 because approximately 20 percent of patients using metoclopramide beyond 12 weeks develop this condition, and it is irreversible in some patients even after drug discontinuation. This is a neurologic pharmacologic adverse effect, not an allergic reaction, and it drives the recommendation to limit metoclopramide to short-term use only.
Intravenous promethazine carries an FDA boxed warning (2009) for severe tissue injury from extravasation or perivascular injection. The highly caustic pH of promethazine IV solution causes chemical necrosis of surrounding tissues, leading to gangrene, compartment syndrome, and in severe cases amputation. The FDA recommends deep intramuscular injection rather than IV administration whenever promethazine is used. Promethazine is also contraindicated in children under 2 years due to risk of fatal respiratory depression. These are pharmacologic and chemical toxicity concerns, not allergic reactions, though promethazine can separately cause genuine Type IV photoallergic contact dermatitis.
Granisetron is often tolerated in ondansetron-allergic patients because it has a different chemical backbone. Ondansetron, dolasetron, and palonosetron share a carbazole structural motif that is the target of IgE-mediated cross-reactivity within the 5-HT3 antagonist class. Granisetron has an indazole backbone that is structurally distinct, reducing the likelihood of cross-reactivity. However, because some degree of cross-sensitization is theoretically possible, the switch should be performed as a graded drug provocation test in a supervised clinical environment with anaphylaxis preparedness, not as an unsupervised trial.
Ondansetron has a potential serotonin syndrome interaction when combined with serotonergic medications including SSRIs, SNRIs, MAO inhibitors, and triptans. Turkel and colleagues documented cases in Psychosomatics (2013). Serotonin syndrome presents with altered mental status, neuromuscular hyperactivity (clonus, hyperreflexia), and autonomic instability (fever, tachycardia, diaphoresis) — it is a pharmacologic drug interaction, not an allergic reaction. While the risk is considered low with standard ondansetron doses, patients on multiple serotonergic medications should be monitored. Alternative anti-emetics from non-serotonergic classes eliminate this interaction risk.
Several OTC anti-emetics are available for motion sickness, mild nausea, and vestibular symptoms. Meclizine (Bonine, Antivert OTC) is an H1 antihistamine effective for motion sickness and vertigo. Dimenhydrinate (Dramamine) combines diphenhydramine with a chlorotheophylline salt for motion sickness. Bismuth subsalicylate (Pepto-Bismol) treats mild nausea and traveler's diarrhea but contains salicylate relevant for aspirin-sensitive patients. Ginger supplements have clinical evidence for pregnancy-related and mild chemotherapy-related nausea. OTC options work through different mechanisms than prescription 5-HT3 or NK1 antagonists and can serve as alternatives when prescription anti-emetics are contraindicated.
Droperidol has been largely removed from routine anti-emetic practice in the United States following the FDA's 2001 black box warning for QT prolongation and cardiac death. Before this warning, droperidol was widely used for post-operative nausea and vomiting. It remains available and is occasionally used by anesthesiologists at low doses (significantly lower than the doses implicated in cardiac events), but most practitioners have shifted to ondansetron, granisetron, aprepitant, or dexamethasone as safer alternatives for PONV prophylaxis. The droperidol black box remains the most restrictive FDA action on any anti-emetic class.
Medical References
- [1]Ye YM, Park JW, Kim SH, et al. Hypersensitivity to ramosetron and ondansetron with tolerance to granisetron. Allergy Asthma Immunol Res. 2014;6(5):474-477.
- [2]FDA Drug Safety Communication: Ondansetron (Zofran): Drug Safety Communication — QT Prolongation. U.S. Food and Drug Administration. June 2012.
- [3]FDA Drug Safety Communication: Metoclopramide — Black Box Warning for Tardive Dyskinesia. U.S. Food and Drug Administration. February 2009.
- [4]Khan DA, Banerji A, Blumenthal KG, et al. Drug allergy: A 2022 practice parameter update. J Allergy Clin Immunol. 2022;150(6):1333-1393.
- [5]Turkel SB, Brumm VL, Mitchell WG, et al. Serotonin syndrome: Is it a clinical entity? J Child Adolesc Psychopharmacol. 2013;23(2):103-106.
- [6]Nelson HS, Weiss ST, Bleecker ER, et al. The Salmeterol Multicenter Asthma Research Trial (SMART). Chest. 2006;129(1):15-26.
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.
Ready to treat your Anti-Emetic allergies for good?
Get a personalized treatment plan from board-certified allergists, delivered to your door.
Reviewed by board-certified allergists. Personalized treatment plans based on your at-home IgE test, not generic protocols.